Microcap Ledger Sunshine Biopharma Inc. $SBFM
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Fort Lauderdale, FL
- Fiscal year end
- December 31
- Shares outstanding
- 3,877,337 [10-Q 2026-08-13]
What the company doesAI summary of filing
Sunshine Biopharma is a pharmaceutical company with commercial operations and a drug development program. Through its subsidiary Nora Pharma, the company markets 71 generic prescription drugs in Canada and has 22 additional drugs in its pipeline. Through its subsidiary Sunshine Canada, the company develops and sells over-the-counter supplements. The company also conducts proprietary drug development for K1.1 mRNA, an mRNA therapy for liver cancer currently in animal testing, and SBFM-PL4, a protease inhibitor for SARS coronavirus treatment also in animal testing. [10-K 2026-04-03]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $17.35M | −$2.81M | −$2.99M | $13.75M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $36.31M | −$5.98M | −$5.33M | $9.12M | [10-K 2026-04-03] |
| FY ended Dec 2024 | $34.87M | −$5.13M | −$12.52M | $9.69M | [10-K 2026-04-03] |
- Quarterly cash burn
- −$1.50M
- Cash runway Estimate
- ~27.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 1,999,660 | [10-Q 2024-11-05] |
| 2025-03-21 | 2,707,541 | [10-K 2025-04-01] |
| 2025-05-15 | 4,555,945 | [10-Q 2025-05-15] |
| 2025-08-12 | 4,555,945 | [10-Q 2025-08-12] |
| 2025-11-13 | 4,905,945 | [10-Q 2025-11-13] |
| 2026-04-02 | 4,905,945 | [10-K 2026-04-03] |
| 2026-05-13 | 5,005,945 | [10-Q 2026-05-13] |
| 2026-08-13 | 3,877,337 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2026-10-02; declared effective 2026-10-07 [S-1 2026-10-02]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-07 | Natan David | grant | 58,300 | — | [4 2026-08-11] |
| 2026-04-14 | Natan David | grant | 100,000 | — | [4 2026-04-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Material agreement entered; Other events |
| 2026-10-09 | 424B4 | Prospectus or prospectus supplement |
| 2026-10-05 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-10-02 | S-1 | Registration statement |
| 2026-09-16 | 8-K | Shareholder vote results |
| 2026-09-11 | 8-K | Other events |
| 2026-09-08 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-28 | S-1 | Registration statement |
| 2026-08-28 | 8-K | Director or officer change |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $SBFM
Email me when Sunshine Biopharma Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.